PROTECT-Cog adds a global test of coached lifestyle plus a metabolism-targeting drug to slow cognitive decline. For people with mild cognitive impairment (MCI), the limit is direct: it studies prevention in at-risk unimpaired adults, not MCI treatment. The Alzheimer's Association launched the $100 million trial July 13, 2026, at AAIC 2026 in London, according to the Association launch announcement. It pairs lifestyle coaching with a drug approach to reduce decline, MCI onset, and dementia.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who is studied and what is compared?
- How does the lifestyle program build on U.S. POINTER?
- Why doesn't this test MCI treatment?
- What should MCI families do now?
Who is studied and what is compared?
PROTECT-Cog will enroll older adults at higher risk for decline. Medscape reports intensive coaching faces a lighter-touch version. A metabolic drug joins lifestyle for a subset over three years, with checks every six months, described in the Medscape trial summary.
Medscape reports the drug was not final at launch. Reports describe a GLP-1 receptor agonist or similar metabolism/immune-modulating agent. The comparison is lifestyle plus drug versus lifestyle alone.
How does the lifestyle program build on U.S. POINTER?
PROTECT-Cog builds directly on U.S. POINTER. NeurologyLive reports POINTER ran two years at five sites with 2,111 cognitively unimpaired at-risk adults.
Structured lifestyle beat self-guided care by 0.029 SD per year in global cognition, detailed in the NeurologyLive POINTER summary. POINTER's structured arm used facilitated group support plus daily habits. NeurologyLive lists 38 facilitated team meetings plus: That mix matters. It supports a multidomain push rather than one single habit.
- supervised aerobic and resistance exercise
- MIND-diet coaching
- cognitive training
- health monitoring
Why doesn't this test MCI treatment?
The Alzheimer's Association frames PROTECT-Cog around at-risk unimpaired adults. It tracks new MCI onset. It does not test MCI treatment or reversal.
The National Institute on Aging defines MCI as memory or thinking problems beyond normal aging that still allow daily activities. Not everyone with MCI develops Alzheimer's. Delaying onset differs from preventing dementia.
What should MCI families do now?
PROTECT-Cog has no efficacy results yet. MedicalDaily notes follow-up will take years in the MedicalDaily trial update.
Clinicians should continue proven vascular-risk care, exercise, diet, sleep, and monitoring meanwhile. Ask the care team what raises personal risk and what helps control it. Keep exercise, MIND-style meals, sleep, and blood-pressure and health visits steady while the three-year follow-up runs.
You Might Also Like
- Why 2026 p-tau217 Research Is Not Population Screening: Study Design and Evidence Limits for People With Mild Cognitive Impairment
- NIA’s 2026 Big Data for Aging Research Workshop: Study Design and Evidence Limits for People With Mild Cognitive Impairment
- Subjective Cognitive Decline Data for Public Health Action in 2026: What the News Means for Adults Over 65





